From the Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada (Park, Balas); Department of Ophthalmology & Vision Sciences, University of Toronto, Toronto, Ontario, Canada (Popovic, El-Defrawy, Kertes); Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada (Alaei); Kensington Eye Institute, Toronto, Ontario, Canada (El-Defrawy); John and Liz Tory Eye Centre, Sunnybrook Health Sciences Centre, Toronto, Canada (Kertes).
Corresponding author: Peter J. Kertes, MD, CM, FRCSC, John and Liz Tory Eye Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Room M1-202a, Toronto, ON M4N 3M5, Canada. Email: [email protected].
Disclosures: M.M. Popovic: financial support (to institution)—PSI Foundation. P.J. Kertes: advisory board—Novartis Corp., Alcon Laboratories, Inc., Bayer Healthcare AG, and Allergan, Inc.; financial support (to institution)—Allergan, Inc.., Bayer Healthcare AG, Roche Innovatis AG, and Novartis Corp.; financial support—Novartis Corp., Bayer Healthcare AG, and Carl Zeiss Meditec AG; scientific advisory board—Novelty Nobility; and equity owner—ArcticDx.
First author:Jeff Park, BHSc, MD(C)Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada